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Abstract
Treatment options for Hepatitis C infection have greatly improved with direct-acting antiviral
(DAA) combinations achieving high cure rates. Nevertheless, the cost of this treatment is still
high and access to treatment in many countries has been preferentially reserved for patients
with more severe fibrosis (F3 and F4). In this French nationwide study, we investigated the
epidemiological characteristics and genotype distribution of hepatitis C virus (HCV) in treat-
ment-naive patients with METAVIR fibrosis stages between F0 and F2 in order to identify
patient profiles that became eligible for unrestricted treatment in a second period. Between
2015 and 2016 we collected data from nine French university hospitals on a total of 584
HCV positive patients with absent, mild or moderate liver fibrosis. The most represented gen-
otypes were genotype 1b (159/584; 27.2%), followed by genotype 1a (150/584; 25.7%); geno-
type 3 (87/584: 14.9%); genotype 4 (80/584; 13.7%). Among genotype 4: 4a was
predominantly encountered with 22 patients (27.5% of genotype 4). Genotypes 1b and 1a
are currently the most frequent virus types present in treatment-naive patients with mild
fibrosis in France. They can be readily cured using the available DAA. Nevertheless, non-a/
non-d genotype 4 is also frequent in this population and clinical data on the efficacy of
DAA on these subtypes is missing. The GEMHEP is the French group for study and evalu-
ation of viral hepatitis on a national scale. Data collection on epidemiological and molecular
aspects of viral hepatitis is performed on a regular basis in all main French teaching hospitals
and serves as a basis for surveillance of these infections. Analysis and trends are regularly pub-
lished on behalf of the GEMHEP group. Data collection was performed retrospectively over
the 2015–2016 period, covering nine main university hospitals in France. A total of 584 hepa-
titis C positive patients were included in this study. Genotyping of the circulating viruses
showed a high prevalence of genotypes 1b and 1a in our population. The epidemiology of
hepatitis C is slowly changing in France, particularly as a consequence of the rise of ‘non-a
non-d’ genotype 4 viruses mainly originating from African populations. More data concerning
treatment efficacy of these genotypes is needed in order to guide clinical care.
Introduction
Hepatitis C virus (HCV) infection is still a major public health concern, as shown by alarming
epidemiological data. HCV prevalence is highly variable from one country to another, from
0.1% to 24% of the population, with 71.1 million viraemic people worldwide [1, 2].
According to the French National Agency for HIV and viral hepatitis (ANRS), 192 700 people
live with HCV in France and 59% of them are not aware of their HCV status [3]. The intro-
duction of direct-acting antiviral interferon-free treatment since 2014 has dramatically
improved the rates of sustained viral response (SVR). For example, a combination of sofosbu-
vir and anti-NS5A treatment given to genotype 1-infected patients was associated with SVR
rates from 92% to 99% in real life studies [4, 5]. However, the high cost of these new
anti-HCV drugs has for long limited access to antiviral treatment
for patients with mild to moderate fibrosis scores (METAVIR F0–F2).
In order to limit costs for the French healthcare system, only
patients with specific indications such as severe fibrosis, previous
treatment failure or HIV infection and after individualised med-
ical review were eligible for public funding of treatment [6, 7].
This strategy left many patients with mild fibrosis (F0–F2)
treatment-naïve. Since March 2017, public funding criteria have
been extended and this F0–F2 population is now eligible for anti-
viral therapy. In France, a large number of HCV patients, esti-
mated at 150 000 according to the French health ministry,
remain to be treated [2, 3, 8].
Knowledge of the various hepatitis C genotypes infecting
treatment-naïve patients and their relative prevalence has import-
ant clinical implications. The aim of this study was to investigate
the epidemiological characteristics and distribution of HCV gen-
otypes in treatment-naive patients with a METAVIR fibrosis stage
between F0 and F2, in France [3, 9].
Patients and methods
Patients
Data were collected from nine French tertiary hospitals (Hepato-
Gastroenterology Departments and Laboratories) between 2015
and 2016. All patients were selected anonymously and had signed
an informed consent form for data collection. The selection was
according to the following criteria: absent, mild or moderate
fibrosis; absence of HCV treatment, HCV viral load results avail-
able, sequencing and genotyping performed since 1 January 2015;
and frozen serum samples available in case of need to repeat ana-
lyses. Exclusion criteria were: past or current HCV treatment and/
or liver fibrosis >stage F2. Relevant characteristics including sex,
age, mode of HCV acquisition, invasive and non-invasive meth-
ods used for liver fibrosis assessment (liver biopsy, FibroScan®,
FibroMeter®, FibroTest®, ActiTest®), serum alanine aminotransfer-
ase (ALT) level, comorbidities (HIV or HBV coinfection, alcohol
consumption) and sequencing methods (NS5B, NS3, Core/E1,
innoLIPA) were collected for each patient. Other characteristics
including country of origin or transmission route were recorded
when known. The degree of liver fibrosis was evaluated using
the FibroTest-ActiTest and/or transient elastography performed
using a FibroScan (Echosens, Paris, France) device. Liver fibrosis
was graded on the METAVIR scale from 1 to 4 [10]. Cut-off
values of liver stiffness measurement by FibroScan were applied
as previously described [11]: 2.5–7 kPa absent or early fibrosis
(F0–F1); 7–9 kPa mild fibrosis (F = 2), 9–12 kPa severe fibrosis
(F = 3) and >12 kPa cirrhosis (F = 4). When two fibrosis tests
were available the most severe fibrosis score was attributed as
recommended by the French association for the study of Liver
disease (AFEF) [7]. When the fibrosis score was between F0
and F1, or between F1 and F2, it was classified as ‘F1’ and ‘F2’
respectively. Serum ALT levels were determined locally using vari-
ous manufacturers’ assays. Results were expressed as a multiple of
Fig. 1. Flow chart of patient inclusion in the GEMHEP
study. Patients excluded from the study are indicated
in grey boxes.
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the upper limit of normal (ULN). Plasma viral load was measured
in each centre using CE approved assays according to the manu-
facturers’ instructions and results were expressed in IU/ml.
HCV genotyping and phylogenetic analyses
HCV genotyping was performed locally using NS5B, NS3 and
core sequencing or the Line Probe Assay v2.0 (InnoLiPA). Five
laboratories used only NS5B sequencing techniques, three labora-
tories used 2 genotyping assays (NS5B + core, NS5B + InnoLiPA,
NS5B and NS3) and one laboratory used all three sequencing
methods. Genotyping was determined according to a previously
described algorithm [12–14]. All sequencing data were collected
and analysed in a unique central laboratory. All sequences were
divided into three groups according to the genomic region
(core, NS5B, NS3) and aligned using a MAFFT (Multiple
alignment program for amino acid or nucleotide sequences)
(mafft.cbrc.jp/alignment/software) and a standard algorithm
FFT-NS-2-I [15, 16]. Phylogenetic analysis was visualised by the
neighbour-joining method with 1000 bootstraps [17]. The first
tree containing all sequences was constructed for crude genotype
determination using selected reference sequences obtained from
Genbank. Next, specific trees were built for each genotype to
assess the subtype. The genotyping results from the participant
laboratories were compared to those from the centralised phylo-
genetic analysis.
Statistical analyses
Demographic characteristics are expressed as mean ± standard
deviation (S.D.), as median with interquartile range or as percen-
tages. To compare categorical and nonparametric data we used
the χ2 test and Mann–Whitney or Kruskal–Wallis tests,
respectively. Statistical significance was considered at P < 0.05.
Statistical analyses were conducted using R (Version 0.99.893;
RStudio, 2016).
Univariate and multivariate analyses were performed using the
logistic regression function. The variables at the univariate ana-
lysis with significant association were analysed by multivariate
analysis. Statistical significance of the logistic regression function
was considered at 5%.
Results
Characteristics of treatment-naïve patients with HCV infection
in France
Out of the 722 patients initially selected, 138 patients presented at
least one exclusion criterion (Fig. 1). The demographic character-
istics of the remaining 584 analysed patients are shown in Table 1.
We found a significant difference in HCV infection frequency
between men and women (47% vs. 53%, P = 0.02). The 40–
59-year-old group was the most frequently infected (34%) (Fig. 2).
Distribution of HCV genotypes in treatment-naïve patients in
France
As shown in Table 2, 353 (60.5%) patients harboured a virus of
genotype 1. The HCV genotype 1b was predominant, followed
by genotypes 1a, 3, 4, 2, 5 and genotype 6 (Supplementary
Fig. S1). The recombinant form 2k/1b was found in one patient.
The genotype of this last sample appeared dubious on the phylo-
genetic tree but was confirmed using near-full-length HCV gen-
ome sequencing as described by Trémeaux et al. [18]. Genotype
2 was divided into several subtypes without any of them being
clearly predominant. In contrast, the ‘a’ subtype was the unique
genotype 3 subtype detected in our French HCV population.
Among genotype 4 subtypes: 4a was found in 22 patients
(27.5% of genotype 4) and 4d in 15 patients (18.8%) but we
note that the majority (53.8%; n = 43) were classified as ‘non-a
non-d’. Among them, we found 7 subtypes 4r, 6 4f, 3 4c, 3 4k.
Genotype 1a and genotype 3 were more frequently found in
men than in women (55% vs. 45% (P < 0.01) and 56% vs. 44%
(P = 0.004), respectively) (Supplementary Fig. S2). Conversely
genotype 1b predominated in women (38% vs. 62% (P < 0.001]).
For genotypes 2 to 5 we found no significant difference in distri-
bution between the sexes. The small number of genotype 6
included did not allow to conclude on any sex difference.
Table 1. Characteristics of untreated patients with hepatitis C and fibrosis stage
F0–F2 included in the French GEMHEP study
Characteristics Data
Age, median (interquartile range) 50 (39–58)
Age group, N (%)
18–39 years 145 (25)
40–59 years 305 (52)
60–69 years 83 (14)
>70 years 51 (9)
Sex, N (%)
Male 276 (47)
Female 308 (53)
Duration of HCV infection (yearsa)
Data available for 193 patients
27.6 (±12.8)
Serum HCV RNA (log 10 IU/mla)
Data available for 245 patients
5.9 (±0.75)
Serum ALT (x Normal) 1.5 (±1.2)
HIV co-infection, N (%)
Data available for 338 patients
30 (9)
HBV co-infection, N (%)
Data available for 338 patients
6 (2)
Chronic alcohol intoxication (%)
Data available for 338 patients
96 (28)
Activity stage by ActiTest, N (%)
Data available for 306 patients
A0 83 (27)
A1 127 (42)
A2 64 (21)
A3 32 (10)
Fibrosis stage by Fibrotest/FibroMeter or Fibroscan, N (%)
Data available for 584 patients
F0 160 (28)
F1 328 (56)
F2 96 (16)
N/A, not available.
aMean, ±S.D.
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Genotype distribution also varied according to age group (Fig. 2).
Genotype 1a was mostly observed in the 18–39 and 40–59 age
groups (22.8% and 34.1%, respectively). Genotype 1b was more
frequently observed in older age groups: 60–69s and the over
70s (37.3% and 49.0% respectively). Mean age was significantly
higher for patients infected with genotype 1b than those infected
with genotype 1a (53 ± 16 and 47 ± 11 respectively, P < 0.0001).
In multivariate analyses, females in this cohort were signifi-
cantly older than men and higher fibrosis scores were associated
with older age (P = 0.014 and P < 0.0001, respectively). No rela-
tion between HCV genotype and any other demographic charac-
teristics was observed.
Genotype distribution according to investigator centre was sig-
nificantly different (P < 0.0001) and is shown in Supplementary
Figure 3. The HCV RNA viral load was significantly different
between HCV genotype groups. Genotypes 1a and 2 had higher
HCV RNA concentrations compared to the other groups (P <
0.001). HCV RNA levels below 8 00 000 IU/ml were observed
most frequently in patients with genotypes 1b (36.9%) and 3
(21.5%). In 29 patients the HCV RNA concentration was high
(⩾60 00 000 IU/ml), including in 12 patients with genotype 1a
(41.4%) (Table 2). We found that HCV high viral loads (> 8 00
000 UI/ml and >60 00 000 UI/ml) were significantly associated
with genotypes 1a and 2 (OR 7.772, 95 CI 4.80–12.57; P <
0.0001 and OR 7.648, 95 CI 3.22–18.14, P < 0.0001, respectively)
(Table 3). Multivariate analysis confirmed this association
(Table 4).
Data on the mode of HCV acquisition (nosocomial, intraven-
ous drug use (IVDU) and other modes of HCV transmission) was
available for 287 patients. For 119 patients identified as probable
intravenous drug users (IVDU) genotypes 1a (42%) and 3a
(22.6%) were the most predominant. Of the 87 patients infected
by transfusion of blood products: 27 (31%) were genotype 1b,
17 (19.5%) were genotype 2 and 13 were genotype 1a (15%).
The mode of HCV acquisition was only available for 34 genotype
4-infected patients, of whom 12 were contaminated via IVDU
(genotype 4a and 4d). Among ‘non-a non-d’ genotype 4, the
most common mode of HCV acquisition was not clearly defined
but was neither nosocomial nor IVDU.
Severity of liver disease and HCV genotypes
Mean serum ALT concentration was significantly higher in
patients with genotype 1a than in other groups (P = 0.01),
although the standard deviation for ALT was larger than in
other genotypes. Table 1 shows data on necroinflammatory activ-
ity and fibrosis stage measured by FibroTest® or FibroMeter®. The
fibrosis stage varied across the HCV genotypes (P < 0.001)
(Table 2). Patients with genotype 1a were more often F0 while
genotype 1b infected patients were more likely to be classified
as having F1 or F2 fibrosis. No other specific pattern was observed
for the other subtypes.
Phylogenetic analysis
Phylogenetic analysis was performed using 355 sequences: 330
sequences for the NS5B region (Fig. 3 and Supplementary Figs
4 and 5), 28 sequences for the NS3 region and 6 sequences for
the core coding region. Some discrepancies were found between
the genotype or subtype initially determined locally and that
found using centralized phylogenetic analysis. One sample classi-
fied as genotype 3a by the initial laboratory was eventually iden-
tified as 2a by phylogenetic analysis (sample HC1525). Four
samples (HC1582, HC1523, HC1537 and HC1011) initially deter-
mined as genotype 4a were subsequently identified as 4c, 4f, 4m
and 4w, respectively (Fig. 3). One sample (HC1035) classified
2d by the local laboratory was assessed as a non-subtypable geno-
type 2 in the absence of robust clustering with a known genotype
2 sequence. Phylogenetic analysis of 387 NS5B sequences also
allowed us to identify the subtype for 23 initially non-subtyped
cases (2 for genotype 1, 4 for genotype 2, 5 for genotype 3 and
12 sequences for genotype 4).
Phylogenetic analyses did not reveal any particular clustering
of the French sequences either in the international database, or
among themselves.
Discussion
In this French nationwide multicentre study, we determined the
HCV genotype distribution in a large population of treatment-
Fig. 2. Age distribution of Hepatitis C virus genotypes in treatment naïve patients with fibrosis stage F0–F2 in France,%.
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Table 4. Multivariate analysis of baseline factors for HCV genotypes 1a and 2
1a 2
OR (95CI) P OR (95CI) P
>8 00 000 IU/ml 110 175 (6.722–18.057) <0.0001 20.963 (8.058–54.533) <0.0001
⩾60 00 000 IU/ml 8639 (3.561–20.964) <0.0001 N/M N/M
OR, odds ratio; 95 CI, 95% confident intervals; P: P-value; N/M, not measurable.
Fig. 3. Phylogenetic tree based on NS5B sequences from 43 patients with 25 references for genotype 4. References are indicated in bold in the format:
genotype.subtype_ID of isolate_GenBank assession number. The scale bars indicate the nucleotide substitutions per site. Analysis was performed using MAFFT
software version 7.
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naïve HCV-infected patients with no or low-stage fibrosis.
Genotype 1b was the most common genotype (27.2%), found in
almost all age groups, but more frequently in patients aged over
60 than in younger patients and in women as previously described
[19]. In the previous GEMHEP study conducted in 2005, geno-
types 1b, 3 and 1a were the most frequent (27.6%, 21.1% and
18.6%, respectively) [20]. In the present study, a shift in HCV
genotype occurrence was observed in treatment-naïve patients:
genotype 1a becoming more frequent (to 25.7%), while a decrease
in frequency was observed for genotype 3 (to 14.9%). A similar
pattern of occurrence was seen in the GEHEP 005 Study of
Spanish HCV viraemic patients with genotype 1b found in
41.3% of the patients and genotype 1a and 3 in respectively
24.9% and 19.6% [19]. One possible explanation for this increase
in genotype 1a prevalence could be that it concerns mostly recent
infections. Indeed, patients with subtype 1a were younger (mean
47 years) than those infected with genotype 1b (mean 53 years)
and tended to have a less advanced liver disease with mild to
moderate fibrosis. Genotype 1a was more frequent in patients
with fibrosis stage F0 (28%), compared to genotype 1b, which
was more frequent in patients with fibrosis stage F1 and F2
(28% and 29%, respectively). Our study was not designed to docu-
ment the date of contamination and the only variable available
was the patient’s age. A better assessment of infection duration
would have been an asset so as to better explore the difference
between 1a and 1b infected patients. Viral load variations accord-
ing to the genotypes are difficult to interpret. Higher HCV viral
load with genotype 1a and lower with genotype 3 were already
described without a clear explanation [21, 22].
Genotype 4 appears to be increasing in prevalence (13.8% here,
compared with 9.2% and 9% in the Polaris and previous
GEMHEP studies, respectively) [2, 20]. This, along with the low
median age (46 ± 13) confirms the results of the Spanish
GEHEP 005 study that suggested a recent introduction of geno-
type 4 into southern Europe [19]. Moreover, we found a large
number of ‘non-a non-d’ genotype 4 (7.4% of the total and
53.8% of genotype 4) in patients originating from the Congo
and Cameroon (6/6 of known origin) whereas those infected
with subtypes a or d originated mainly from France (14/20 of
known origin).
Shifts in population characteristics and hence in the prevalence
of genotype 4 subtypes have potential consequences for public
health. A recently published global analysis of HCV genotypes
infecting 12 615 patients included in 67 clinical studies showed
that the ‘non-a non-d’ genotype 4 represented only 0.55% of the
population studied (14% of genotype 4) [23]. These subtypes
may respond differently from genotype 4a or 4d to DAA combina-
tions [24]. We note that genotype 4 ‘non-a non-d’ subtypes present
in the French HCV-infected population are currently under-
represented in clinical studies; therefore, no clear therapeutic rec-
ommendation exists for them. Such information is important if
the current DAA strategy is to be used worldwide with the ambi-
tious goal of eradicating HCV by the year 2030. The unexpected
poor response of specific subtypes to DAA may lead to the selec-
tion of resistant variants, more difficult to eliminate.
Our study highlighted that (i) data from clinical studies lacks
some HCV subtypes that are prevalent in France and even
more prevalent in other parts of the world and (ii) only 17% of
genotype 1a infected patients had a viral load <8 00 000 IU/ml
and the rest would, therefore, be eligible for grazoprevir/elbasvir
therapy as indicated in French recommendations [7]. Moreover,
despite the arrival of theoretically pan-genotypic therapeutic
combinations, differences in activity seem to persist, such as the
lower efficacy of the glecaprevir/pibrentasvir combination on pre-
viously treated genotype 3 or of sofosbuvir/velpatasvir/voxilapre-
vir for 8 weeks on genotype 1a [25–27]. Precise pre-treatment
knowledge of the viral subtype could thus be an important par-
ameter in the therapeutic management of HCV infection and
for the future goal of eradication of this infection.
While this study was not designed to allow a follow-up of the
patients and the achieved SVR rates when treated, data were avail-
able for one centre. In this particular centre, 67 patients were
included in the present study and 43 (64.2%) were treated between
2016 and 2019. Among those 43 patients, at least 27 (62.8%)
achieved SVR.
One limitation of this study was the diversity of HCV genotyp-
ing assays and their interpretation, as shown by the number of
discordant results due to variations in the sequences purchased
by participating laboratories. These differences could be due to
the use of different reference sequence databases. In 23 cases,
the complementary phylogenetic analysis allowed the classifica-
tion of unknown subtypes. Likewise, the use of a complete and
consensual sequence database is crucial to correctly interpret
HCV subtypes. The identification of a suspect NS5B sequence
and its confirmation using a near-full-length genome sequencing
approach, revealing a recombinant form of HCV, was only pos-
sible thanks to the introduction of RF2k/1b sequences into the
database. The detection of other recombinant forms may be
missed by short fragment sequencing, the absence of a reference
recombinant sequence in the database or the use of a 5′UTR/
Core-based Line probe assay [28]. We chose not to ask for
detailed clinical data from each participating laboratory in order
to include as many samples as possible without organisational
restrictions. Furthermore, inclusions were deliberately restricted
so as to focus on untreated patients with no or moderate fibrosis.
This study, while based on a relatively short period, does, how-
ever, reflect the HCV infection spread in the French population
by sampling patients from a large number of centres.
In conclusion, our study precisely describes the characteristics
of HCV genotypes infecting patients who will soon benefit from
expanded treatment indications recently recommended by the
French government. Genotype 1b and 1a are currently the most
frequent viral strains in treatment-naïve patients with mild fibro-
sis stages. Nevertheless, ‘non-a non-d’ genotype 4 is becoming
increasingly frequent in this population and more clinical data
on the efficacy of direct antiviral drugs on these emergent sub-
types is needed.
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